提供支持(VCBeat) July. 29, 2021 -- Wuhan HealthCare Biotechnology Co., Ltd. ("HealthCare") has recently completed an additional Series B financing of tens of millions, co-led by Chuchang Investment and Luojia Capital, with participation from Hubei Provincial High Technology Industry Investment. In previous rounds of financing, YuanBio Venture Capital and Sinopharm Capital also other investors also invested in HealthCare.
Chen Gang, founder and CEO of HealthCare, said the funds raised will be used to consolidate HealthCare's leading position in fluorescence in situ hybridization (FISH) analysis platform, and accelerate the development of technology platforms in the fields of molecular diagnosis of blood tumors.
HealthCare is located in Wuhan Optics Valley Bio-Lake, National Bio-Industry Base. The company is a high-tech enterprise integrating R&D, production, sales and testing services with the strategic direction of precise medical diagnosis products for major diseases such as cancer, cardiovascular and cerebrovascular diseases.
Since its inception, HealthCare has been committed to providing more efficient diagnostic products, with emphasis on independent research and development, and has established multi-disciplinary R&D teams in Clinical Medicine, Molecular Biology, Microfluidics, Mechanical Automation and other disciplines. The company has more than 10 invention patents and its torchbearer FastProbe® FISH probe preparation technology with full independent intellectual property rights is at the international front level. Based on this patented technology, the new generation of probe hybridization incubation time is only 2 hours, shortening the fluorescence in situ hybridization detection time from 3 days to a few hours, with higher sensitivity, specificity and bright signal to noise ratio.
At the same time, HealthCare has built a complete domestic and international marketing system and FastProbe® has entered more than 20 countries, and regions oversea, won a good market reputation and wide customer recognition, and become a leading brand of fast fluorescence in situ hybridization probe in the world.
About Chuchang Investment
Wuhan Chuchang Equity Investment, founded in 2018, is a wholly-owned subsidiary of Chuchang Investment focusing on equity investment in non-listed enterprises, with a registered capital of 30 million yuan. Chuchang Tongtai Fund is the first fund launched by Wuhan Chuchang Equity Investment in the medical and healthcare field, investing in innovative medical equipment, biotechnology, medical services and other tracks.
About Luojia Capital
Luojia Capital was founded in 2014 by prominent Wuhan University alumni entrepreneurs in different industries, including Chen Dongsheng, Lei Jun, Tian Yuan, Mao Zhenhua, Ai Luming, Yan Zhi, and Chen Zuotao. They are committed to investing in and partnering with outstanding entrepreneurs to help them build and grow industry-leading businesses. Luojia Capital focuses on artificial intelligence, environmental protection, new energy, advanced manufacturing, new materials, healthcare and the new generation of information technology and other strategic emerging industries. It participates in the financing rounds covering Series A to pre-IPO.
渝公网安备 50011202502165号
